.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Fuji
Chinese Patent Office
Chubb
Cantor Fitzgerald
Johnson and Johnson
Accenture
Harvard Business School
Daiichi Sankyo

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
Abstract: The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as ARM-HI\'s, function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by recruiting anti-DNP antibodies to gp120-expressing cells, thereby preventing cell infection and spread of HIV. It has been shown that ARM-HI\'s bind to gp120 and gp-120 expressing cells competitively with CD4, thereby decreasing viral infectivity as shown by an MT-2 cell assay, the binding leading to formation of a ternary complex by recruiting anti-DNP antibodies to bind thereto, the antibodies present in the ternary complex promoting the complement-dependent destruction of the gp120-expressing cells. Compounds and methods are described herein.
Inventor(s): Spiegel; David (New Haven, CT), Parker; Christopher (Medina, OH)
Assignee: YALE UNIVERSITY (New Haven, CT)
Application Number:13/988,251
Patent Claims:1. A compound according to the chemical structure: ##STR00070## Where ##STR00071## is an antibody binding terminus (moiety) comprising a moiety according to the chemical structure; ##STR00072## ##STR00073## wherein said DNP group is a dinitrophenyl group linked through the amino group or a thio group to the amino acid; Y' is H or NO.sub.2; X is O, CH.sub.2, NR.sup.1, S(O), S(O).sub.2, --S(O).sub.2O, --OS(O).sub.2, or OS(O).sub.2O; R.sup.1 is H, a C.sub.1-C.sub.3 alkyl group, or a --C(O)(C.sub.1-C.sub.3) group; Xs is OH or NHAc; X.sub.R is O or S; X.sub.M is O or S; X' is CH.sub.2, O, N--R.sup.1' or S; R.sup.1' is H or C.sub.1-C.sub.3 alkyl; Z is a bond, a monosaccharide, disaccharide, oligosaccharide, glycoprotein or glycolipid; Xs is OH or NHAc; X.sup.b is a bond, O, CH.sub.2, NR.sup.1 or S; X'' is O, CH.sub.2, NR.sup.1; and ##STR00074## is a linker molecule which chemical links ABT to R.sup.Y and which optionally includes a connector group CT; ##STR00075## optionally substituted is an aromatic or heteroaromatic group; R.sup.Y is an optionally substituted heteroaryl, or is an optionally substituted aryl group wherein said optionally substituted heteroaryl or said optionally substituted aryl group is selected from the group consisting of imidazole, furyl, pyrrole, furanyl, thiene, thiazole, pyridine, pyrimidine, pyrazine, triazole, oxazole, indole, quinoline, pyridone, pyridazine, pyrazole, triazine, tetrazole, isoindole, indolizine, purine, indazole, isoquinoline, quinolizine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, imidazopyridine, imidazotriazine, pyrazinopyridazine, acridine, phenanthridine, carbazole, carbazoline, perimidine, phenanthroline, phenacene, oxadiazole, benzimidazole, pyrrolopyridine, pyrrolopyrimidine, pyridopyrimidine; thiophene, benzothiophene; furan, pyran, cyclopentapyran, benzofuran, isobenzofuran; thiadizole, isothiazole, benzoxazole, benzothiazole, benzothiadiazole, phenothiazine, isoxazole, furazan, phenoxazine, pyrazoloxazole, imidazothiazole, thienofuran, furopyrrole, pyridoxazine, furopyridine, furopyrimidine, thienopyrimidine, phenyl, naphthyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, thiazolyl, 2-thiazole, 4-thiazole, 5-thiazole, isothiazolyl, oxazole, 2-oxazole, 4-oxazole, 5-oxazole, isoxazolyl, furanyl, 2-furan, 3-furan or thiophenyl, 2-thiophene, 3-thiophene, a bicyclic aryl, benzyl, anthracenyl, and phenanthrenyl; X.sub.2 is --(CH.sub.2).sub.nO--(C.sub.1-C.sub.6 alkyl), --(OCH.sub.2).sub.nO--(C.sub.1-C.sub.6 alkyl), H, --(CH.sub.2).sub.nOH, --(CH.sub.2).sub.nCOOH, optionally substituted C.sub.1-C.sub.6 alkyl, --(CH.sub.2).sub.nC(O)--(C.sub.1-C.sub.6 alkyl), --(CH.sub.2).sub.nNHC(O)--R.sub.1, --(CH.sub.2).sub.nNR.sub.1R.sub.2, --(CH.sub.2).sub.nC(O)--NR.sub.1R.sub.2, --(CH.sub.2O).sub.nH, --(CH.sub.2O).sub.nCOOH, --(CH.sub.2O).sub.nC(O)--(C.sub.1-C.sub.6 alkyl), --(OCH.sub.2).sub.nNHC(O)--R.sub.1, --(CH.sub.2O).sub.nC(O)--NR.sub.1R.sub.2, NO.sub.2, CN or halogen; X.sub.3 is H, --(CH.sub.2).sub.nOH, --(CH.sub.2).sub.nCOOH, optionally substituted C.sub.1-C.sub.6 alkyl, --(CH.sub.2).sub.nO--(C.sub.1-C.sub.6 alkyl), --(CH.sub.2).sub.nC(O)--(C.sub.1-C.sub.6 alkyl), --(CH.sub.2).sub.nNR.sub.1R.sub.2, --(CH.sub.2).sub.nNHC(O)--R.sub.1, --(CH.sub.2).sub.nC(O)--NR.sub.1R.sub.2, --(CH.sub.2O).sub.nH, --(CH.sub.2O).sub.nCOOH, --(OCH.sub.2).sub.nO--(C.sub.1-C.sub.6 alkyl), --(CH.sub.2O).sub.nC(O)--(C.sub.1-C.sub.6 alkyl), --(OCH.sub.2).sub.nNHC(O)--R.sub.1, --(CH.sub.2O).sub.nC(O)--NR.sub.1R.sub.2, NO.sub.2, CN, halogen or a monocyclic aryl or heteroaryl group which itself is optionally substituted; R.sup.1 is H or a C.sub.1-C.sub.3 alkyl group; R.sub.1 and R.sub.2 are each independently H or a C.sub.1-C.sub.6 alkyl group; i is 1 or 0; k is 0, 1, 2 or 3; n is 0, 1, 2, 3, 4, 5, 6; Y.sub.3 is H or a C.sub.1-C.sub.3 alkyl group; and R.sup.N is H or a C.sub.1-C.sub.3 alkyl group which is optionally substituted with one or two hydroxyl groups or up to three halogen groups, or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof, wherein the term "substituted" shall mean substituted at a carbon or nitrogen position with hydroxyl, carboxyl, cyano (C.ident.N), nitro (NO.sub.2), halogen, C.sub.1-C.sub.10 alkyl, substituted phenyl, benzyl, benzoyl, C.sub.1-C.sub.6 alkoxy, aryl ester, C.sub.1-C.sub.6 alkylene ester, where substitution occurs on the alkylene group, rather than at the ester function, aryl, a five- or six-membered cyclic alkylene amine, a C.sub.1-C.sub.6 alkyl amine, a C.sub.1-C.sub.6 dialkyl amine which alkyl groups may be substituted with one or two hydroxyl groups, an amido group substituted with one or two C.sub.1-C.sub.6 alkyl groups, carboxamide, which is substituted with one or two C.sub.1-C.sub.6 alkyl groups, C.sub.1-C.sub.6 alkyl or aryl alkanol or C.sub.1-C.sub.6 alkyl or aryl alkanoic acid.

2. The compound according to claim 1 according to the formula: ##STR00076## where ##STR00077## is a monocyclic or bicyclic aryl or heteroaryl group according to the chemical structure: ##STR00078## Where W is H, --(CH.sub.2).sub.nOH, --(CH.sub.2)--COOH, C.sub.1-C.sub.6 alkyl, --(CH.sub.2).sub.nO--(C.sub.1-C.sub.6 alkyl), --(CH.sub.2).sub.nC(O)--(C.sub.1-C.sub.6 alkyl), --(CH.sub.2).sub.nNHC(O)--R.sub.1, --(CH.sub.2).sub.nC(O)--NR.sub.1R.sub.2, --(CH.sub.2O).sub.nOH, --(CH.sub.2O).sub.nCOOH, --CH.sub.2O).sub.nO--(C.sub.1-C.sub.6 alkyl), --(CH.sub.2O).sub.nC(O)--(C.sub.1-C.sub.6 alkyl), --(CH.sub.2O).sub.bNHC(O)--R.sub.1, --(CH.sub.2O).sub.nC(O)--NR.sub.1R.sub.2, NO.sub.2, CN, halogen (F, Cl, Br, I) or a monocyclic aryl or heteroaryl group which itself is optionally substituted; W' is H, --(CH.sub.2).sub.nOH, --(CH.sub.2).sub.nCOOH, C.sub.1-C.sub.6 alkyl, --(CH.sub.2).sub.nO--(C.sub.1-C.sub.6 alkyl) or halogen; ##STR00079## is a group according to chemical structure: ##STR00080## Where W.sup.2 is H, --(CH.sub.2).sub.nOH, --(CH.sub.2).sub.nCOOH, C.sub.1-C.sub.6 alkyl, --(CH.sub.2).sub.nO--(C.sub.1-C.sub.6 alkyl), --(CH.sub.2).sub.nC(O)--(C.sub.1-C.sub.6 alkyl), --(CH.sub.2).sub.nNHC(O)--R.sub.1, --(CH.sub.2).sub.nC(O)--NR.sub.1R.sub.2, --(CH.sub.2O).sub.nOH, --(CH.sub.2O).sub.nCOOH, C.sub.1-C.sub.6 alkyl, --(CH.sub.2O).sub.nO--(C.sub.1-C.sub.6 alkyl), --(CH.sub.2O).sub.nC(O)--(C.sub.1-C.sub.6 alkyl), --(CH.sub.2O).sub.nNHC(O)--R.sub.1, --(CH.sub.2O).sub.nC(O)--NR.sub.1R.sub.2, NO.sub.2, CN or halogen; X in ##STR00081## is a group --(CH.sub.2).sub.n'NHC(O)--, --(CH.sub.2).sub.n'NH--, --(CH.sub.2).sub.n'O--, --(CH.sub.2).sub.m--, --(CH.sub.2).sub.n'S--, --(CH.sub.2).sub.n'S(O)--, --(CH.sub.2).sub.n'SO.sub.2-- or --(CH.sub.2).sub.n'NH--C(O)--NH-- which links ##STR00082## to the linker; Y is O, S or N--R where R is H or a C.sub.1-C.sub.3 alkyl group; X.sub.2 is --(CH.sub.2O).sub.nO--(C.sub.1-C.sub.6 alkyl), H, --(CH.sub.2).sub.nOH, --(CH.sub.2).sub.nCOOH, C.sub.1-C.sub.6 alkyl, --(CH.sub.2).sub.nO--(C.sub.1-C.sub.6 alkyl), --(CH.sub.2).sub.nC(O)--(C.sub.1-C.sub.6 alkyl), --(CH.sub.2).sub.nNHC(O)--R.sub.1, --(CH.sub.2).sub.nC(O)--NR.sub.1R.sub.2, --(CH.sub.2O).sub.nOH, --(CH.sub.2O).sub.nCOOH, C.sub.1-C.sub.6 alkyl, --(CH.sub.2O).sub.nC(O)--(C.sub.1-C.sub.6 alkyl), --(CH.sub.2O).sub.nNHC(O)--R.sub.1 or --(CH.sub.2O).sub.nC(O)--NR.sub.1R.sub.2, NO.sub.2; R.sub.1 and R.sub.2 are each independently H or a C.sub.1-C.sub.6 alkyl group; Y.sub.3 is H or a C.sub.1-C.sub.3 alkyl group disposed out of or into the plane on the chiral carbon; and R.sup.N is H or a C.sub.1-C.sub.3 alkyl group which is optionally substituted with one or two hydroxyl groups or up to three halogen groups; i is 1 or 0; and m is 1, 2, 3, 4 or 5; n is 0, 1, 2, 3, 4, 5 or 6; and n' is 0, 1, 2 or 3; ##STR00083## is the same as in claim 1; and ##STR00084## is a linker molecule which links ##STR00085## to X and optionally includes a connector group CT; or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof.

3. The compound according to claim 1 wherein ABT is a) a moiety according to the chemical structure; ##STR00086## where X.sup.b is a bond, 0, CH.sub.2, NR.sup.1 or S; or b) a moiety according to the chemical structure: ##STR00087## Where Y' is H or NO.sub.2; X is O, CH.sub.2, NR.sup.1, S(O), S(O).sub.2, --S(O).sub.2O, --OS(O).sub.2, or OS(O).sub.2O; and R.sup.1 is H, a C.sub.1-C.sub.3 alkyl group, or a --C(O)(C.sub.1-C.sub.3) group; or c) a chemical group according to the chemical structure: ##STR00088## where DNP is a dinitrophenyl group linked to the amino acid through an amine or thio group or d) a group according to the chemical structure: ##STR00089## Where X.sub.R is O or S; and X.sub.M is O or S.

4. The compound according to claim 1 wherein R.sup.Y is an optionally substituted furanyl, tetrazolyl, phenyl, naphthyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, or thiophenyl group.

5. The compound according to claim 1 wherein said ARYL group is an optionally substituted phenyl group.

6. The compound to claim 1 wherein R.sup.N is H, X.sub.2 is H or OCH.sub.3; X.sub.3 is H, OCH.sub.3, CH.sub.3 or NO.sub.2; Y.sub.3 is H or CH.sub.3 (racemic or enantiomeric); and k and i are each 1, or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof.

7. The compound according to claim 1 wherein Y.sub.3 is a CH.sub.3 group and said CH.sub.3 group is disposed outward from the plane.

8. The compound according to claim 1 wherein R.sup.Y is an optionally substituted furanyl group.

9. The compound according to claim 2 wherein [ARYL2] is a ##STR00090## group.

10. The compound according to claim 2 wherein said linker comprises a group according to the formula: ##STR00091## where each n is independently 0, 1, 2, 3, 4, 5 or 6 or a polyethylene glycol having from 1 to 12 glycol units.

11. A compound according to claim 10 according to the chemical structure: ##STR00092## or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 10 wherein said polyethylene glycol linker has 1 to 10 glycol units.

13. The compound according to claim 10 wherein said polyethylene glycol linker has 1 to 6 glycol units.

14. The compound according to claim 2 wherein said [ARYL1] group is selected from the group consisting of phenyl, o-, m-, or p-toluyl, o-, m- or p-ethylphenyl, o-, m- or p-isopropylphenyl, naphthyl, o-, m- or p-phenol, 3,5-dihydroxylphenyl, o-, m- or p-hydroxymethylphenyl or a 2-, 3-, or 4-pyridyl group.

15. The compound according to claim 1 wherein said [ARYL] group is selected from the group consisting of phenyl, o-, m-, or p-toluyl, o-, m- or p-ethylphenyl, o-, m- or p-isopropylphenyl, naphthyl, o-, m- or p-phenol, 3,5-dihydroxylphenyl, o-, m- or p-hydroxymethylphenyl or a 2-, 3-, or 4-pyridyl group.

16. The compound according to claim 1 wherein said ABT moiety comprises a group according to the chemical formula: ##STR00093## Where Y' is H or NO.sub.2; X is NR.sup.1, O, CH.sub.2, S(O), S(O).sub.2, --S(O).sub.2O, --OS(O).sub.2, or OS(O).sub.2O; and X.sub.R is O or S.

17. The compound according to claim 1 wherein said linker is ##STR00094## Where R.sub.a is H, C.sub.1-C.sub.3 alkyl or alkanol or forms a cyclic ring with R.sup.3 and R.sup.3 is a side chain derived from an amino acid; and m is an integer from 1 to 15.

18. The compound according to claim 9 according to the chemical structure: ##STR00095## where each n is independently 0, 1, 2, 3, 4, 5 or 6.

19. The compound according to claim 1 wherein said linker is a compound according to the chemical formula: ##STR00096## where Z and Z' are each independently a bond, --(CH.sub.2).sub.i--O, --(CH.sub.2).sub.i--S, --(CH.sub.2).sub.i--N--R, ##STR00097## wherein said --(CH.sub.2).sub.i group, if present in Z or Z', is bonded to a connector, ABT or CBT; Each R is H, or a C.sub.1-C.sub.3 alkyl or alkanol group; Each R.sup.2 is independently H or a C.sub.1-C.sub.3 alkyl group; Each Y is independently a bond, O, S or N--R; Each i is independently 1 to 50; D is ##STR00098## or a bond, with the proviso that Z, Z' and D are not each simultaneously bonds; j is 1 to 100; m' is 1 to 100; n is 1 to 100; X.sup.1 is O, S or N--R; and R is as described above, or a pharmaceutically acceptable salt, solvate or polymorph thereof.

20. The compound according to claim 2 wherein said linker is a compound according to the chemical formula: ##STR00099## where Z and Z' are each independently a bond, --(CH.sub.2).sub.i--O, --(CH.sub.2).sub.i--S, --(CH.sub.2).sub.i--N--R, ##STR00100## wherein said --(CH.sub.2).sub.i group, if present in Z or Z', is bonded to a connector, ABT or CBT; Each R is H, or a C.sub.1-C.sub.3 alkyl or alkanol group; Each R.sup.2 is independently H or a C.sub.1-C.sub.3 alkyl group; Each Y is independently a bond, O, S or N--R; Each i is independently 1 to 50; D is ##STR00101## or a bond, with the proviso that Z, Z' and D are not each simultaneously bonds; j is 1 to 100; m' is 1 to 100; n is 1 to 100; X.sup.1 is O, S or N--R; and R is as described above, or a pharmaceutically acceptable salt, solvate or polymorph thereof.

21. The compound according to claim 2 wherein X.sub.2 is OCH.sub.3 or H; ##STR00102## is a group according to chemical structure: ##STR00103## where Y is O; X is a group --(CH.sub.2).sub.nNHC(O)--, --(CH.sub.2).sub.nNH--, --(CH.sub.2).sub.nO--, --(CH.sub.2).sub.m--, --(CH.sub.2).sub.nS--, --(CH.sub.2).sub.nS(O)--, --(CH.sub.2).sub.n SO.sub.2-- or --(CH.sub.2).sub.nNH--C(O)--NH--; W.sup.2 is H R.sup.N is H; Y.sub.3 is H or a CH.sub.3 group disposed outward from the plane; ABT comprises a ##STR00104## group or a ##STR00105## group where X.sub.R is O or S; ##STR00106## is a linking group comprising a polyethylene glycol having from 1 to 8 glycol units; i is 1; m is 1, 2, 3, 4 or 5; Each n is independently 0, 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof.

22. The compound according to claim 2 wherein X.sub.2 is H or OCH.sub.3; ##STR00107## W is H or NO.sub.2; ##STR00108## Y is O; X is a group --(CH.sub.2).sub.nNH--, --(CH.sub.2).sub.nNHC(O)--, --(CH.sub.2).sub.nO--, --(CH.sub.2).sub.nS--, --(CH.sub.2).sub.nS(O)--, --(CH.sub.2).sub.nSO.sub.2-- or --(CH.sub.2).sub.nNH--C(O)--NH--; R.sup.N is H; Y.sub.3 is H or a CH.sub.3 group disposed outward from the plane; ABT comprises a ##STR00109## group or a or a ##STR00110## group where X.sub.R is O or S; ##STR00111## is a linking group comprising a polyethylene glycol having from 1 to 8 glycol units; i is 1; m is 1, 2, 3, 4 or 5; and Each n is independently 0, 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof.

23. The compound: ##STR00112## where each n is independently 0, 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof.

24. The compound according to claim 22 which is: ##STR00113##

25. A pharmaceutical composition comprising an effective amount of a bifunctional compound according to claim 1 in combination with a pharmaceutically acceptable carrier, additive or excipient.

26. The composition according to claim 25 wherein said composition further comprises an effective amount of an additional anti-HIV agent.

27. The composition according to claim 26 wherein said additional anti-HIV agent is selected from the group consisting of nucleoside reverse transcriptase inhibitors (NRTI), non-nucloeoside reverse transcriptase inhibitors, protease inhibitors and fusion inhibitors.

28. The composition according to claim 26 wherein said additional anti-HIV agent is selected from the group consisting of Amprenivir, Abacavir, Acemannan, Acyclovir, AD-439, AD-519, Adefovir dipivoxil, Alpha Interferon, Ansamycin, 097, AR 177, Beta-fluoro-ddA, BMS-232623 (CGP-73547), BMS-234475 (CGP-61755), CI-1012, Cidofovir, Curdlan sulfate, Cytomegalovirus Immune globin, Ganciclovir, Dideoxyinosine, DMP-450, Efavirenz (DMP-266), EL10, Famciclovir, FTC, GS 840, HBY097, Hypericin, Recombinant Human Interferon Beta, Interferon alfa-n3, Indinavir, ISIS-2922, KNI-272, Lamivudine (3TC), Lobucavir, Nelfinavir, Nevirapine, Novapren, Peptide T Octapeptide Sequence, Trisodium Phosphonoformate, PNU-140690, Probucol, RBC-CD4, Ritonavir, Saquinavir, Valaciclovir, Virazole Ribavirin, VX-478, Zalcitabine, Zidovudine (AZT), Tenofovir diisoproxil fumarate salt, Combivir, Abacavir succinate, T-20, AS-101, Bropirimine, CL246, EL10, FP-21399, Gamma Interferon, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), HIV Core Particle Immunostimulant, Interleukin-2 (IL-2), Immune Globulin Intravenous, IMREG-1, IMREG-2, Imuthiol Diethyl Dithio Carbamate, Alpha-2 Interferon, Methionine-Enkephalin, MTP-PE (Muramyl-Tripeptide), Granulocyte Colony Stimulating Factor (GCSF), Remune, rCD4 (Recombinant Soluble Human CD4-IgG), rCD4-IgG Hybrids, Recombinant Soluble Human CD4, Interferon Alfa 2a, SK&F1-6528, Soluble T4, Thymopentin, Tumor Necrosis Factor (TNF), AK602, Alovudine, Amdoxovir, AMD070, Atazanavir (Reyataz), AVX754 (apricitabine), Bevirimat, BI-201, BMS-378806, BMS-488043, BMS-707035, C31G, Carbopol 974P, Calanolide A, Carrageenan, Cellulose sulfate, Cyanovirin-N, Darunavir, Delavirdine, Didanosine (Videx), Efavirenz, Elvucitabine, Emtricitabine, Fosamprenavir (Lexiva), Fozivudine tidoxil, GS 9137, GSK-873,140 (aplaviroc), GSK-364735, GW640385 (brecanavir), HG0004, HGTV43, INCB9471, KP-1461, Lopinavir, Mifepristone (VGX410), MK-0518, PPL-100, PRO 140, PRO 542, PRO 2000, Racivir, SCH-D (vicriviroc), SP01A, SPL7013, TAK-652, Tipranavir (Aptivus), TNX-355, TMC125 (etravirine), UC-781, UK-427,857 (Maraviroc), Valproic acid, VRX496, Zalcitabine, Valganciclovir, Clindamycin with Primaquine, Fluconazole Pastille, Nystatin Pastille, Eflornithine, Pentamidine, Isethionate, Trimethoprim, Trimethoprim/sulfa, Piritrexim, Pentamidine isethionate, Spiramycin, Intraconazole-R51211, Trimetrexate, Daunorubicin, Recombinant Human Erythropoietin, Recombinant Human Growth Hormone, Megestrol Acetate, Testosterone, Aldesleukin (Proleukin), Amphotericin B, Azithromycin (Zithromax), Calcium hydroxyapatite, Doxorubicin, Dronabinol, Entecavir, Epoetin alfa, Etoposide, Fluconazole, Isoniazid, Itraconazole (Sporanox), Megestrol, Paclitaxel (Taxol), Peginterferon alfa-2, Poly-L-lactic acid (Sculptra), Rifabutin (Mycobutin), Rifampin, Somatropin and Sulfamethoxazole/Trimethoprim.

29. The composition according to claim 26 wherein said additional anti-HIV agent is selected from the group consisting of 3TC (Lamivudine), AZT (Zidovudine), (-)-FTC, ddI (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-FddC, L-FD4C, NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV (Nelfinavir), APV (Amprenavir), LPV (Lopinavir), T20, fuseon and mixtures thereof.

30. The composition according to claim 25 in oral dosage form.

31. The composition according to claim 25 in parenteral dosage form.

32. The composition according to claim 25 in topical dosage form.

33. The composition according to claim 31 wherein said parenteral dosage form is an intravenous dosage form.

Summary for Patent: ► Subscribe

PCT Information
PCT FiledNovember 17, 2011PCT Application Number:PCT/US2011/061174
PCT Publication Date:May 24, 2012PCT Publication Number: WO2012/068366

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Amgen
EPOGEN/PROCRIT
epoetin alfa
VIAL; SINGLE-USE1032340011989-06-01► Subscribe YALE UNIVERSITY (New Haven, CT) Spiegel; David (New Haven, CT), Parker; Christopher (Medina, OH) ► SubscribeRXsearch
Amgen
EPOGEN/PROCRIT
epoetin alfa
VIAL; MULTIDOSE1032340021989-06-01► Subscribe YALE UNIVERSITY (New Haven, CT) Spiegel; David (New Haven, CT), Parker; Christopher (Medina, OH) ► SubscribeRXsearch
Amgen
EPOGEN/PROCRIT
epoetin alfa
VIAL; MULTIDOSE1032340031989-06-01► Subscribe YALE UNIVERSITY (New Haven, CT) Spiegel; David (New Haven, CT), Parker; Christopher (Medina, OH) ► SubscribeRXsearch
Amgen
EPOGEN/PROCRIT
epoetin alfa
VIAL; SINGLE-USE1032340041989-06-01► Subscribe YALE UNIVERSITY (New Haven, CT) Spiegel; David (New Haven, CT), Parker; Christopher (Medina, OH) ► SubscribeRXsearch
Amgen
EPOGEN/PROCRIT
epoetin alfa
VIAL; SINGLE-USE1032340051989-06-01► Subscribe YALE UNIVERSITY (New Haven, CT) Spiegel; David (New Haven, CT), Parker; Christopher (Medina, OH) ► SubscribeRXsearch
Amgen
EPOGEN/PROCRIT
epoetin alfa
VIAL; SINGLE-USE1032340061989-06-01► Subscribe YALE UNIVERSITY (New Haven, CT) Spiegel; David (New Haven, CT), Parker; Christopher (Medina, OH) ► SubscribeRXsearch
Amgen
EPOGEN/PROCRIT
epoetin alfa
VIAL; SINGLE-USE1032340071989-06-01► Subscribe YALE UNIVERSITY (New Haven, CT) Spiegel; David (New Haven, CT), Parker; Christopher (Medina, OH) ► SubscribeRXsearch
Chiron
PROLEUKIN
aldesleukin
VIAL1032930011992-05-05► Subscribe YALE UNIVERSITY (New Haven, CT) Spiegel; David (New Haven, CT), Parker; Christopher (Medina, OH) ► SubscribeRXsearch
Interferon Sciences
ALFERON N INJECTION
interferon alfa-n3
VIAL1031580011989-10-10► Subscribe YALE UNIVERSITY (New Haven, CT) Spiegel; David (New Haven, CT), Parker; Christopher (Medina, OH) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Australia2011329829Feb 09, 2017
Australia2011329829Jul 11, 2013
Brazil112013012309Aug 23, 2016
Canada2818308May 24, 2012
Chile2013001429Apr 11, 2014
China103402998Nov 20, 2013
China107011333Aug 04, 2017
Colombia6801635Nov 29, 2013
Eurasian Patent Organization201390726Jun 30, 2014
European Patent Office2640720May 28, 2014
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
UBS
QuintilesIMS
Fish and Richardson
Teva
McKinsey
US Army
Fuji
Chinese Patent Office
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot